Pablo Corral Shares Insights on Remnant Cholesterol and Its Role in Atherosclerotic Cardiovascular Disease
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Remnant cholesterol: the overlooked driver of residual risk in ASCVD
Despite achieving LDL-C targets with statins and novel lipid-lowering therapies, patients remain exposed to substantial residual cardiovascular risk. Emerging evidence highlights remnant cholesterol (RC)—the cholesterol content of triglyceride-rich lipoproteins—as a causal factor in atherosclerosis.
Epidemiological, genetic, and mechanistic studies consistently show that elevated RC predicts major adverse cardiovascular events, independently of LDL-C. Mendelian randomization confirms a causal role, while clinical data suggest that RC promotes endothelial dysfunction, inflammation, and thrombosis.
Although lifestyle interventions remain essential, pharmacologic strategies—including statins, fibrates, PCSK9 inhibitors, and novel gene-targeted therapies—can reduce RC levels. However, standardized measurement and clear therapeutic targets are still lacking.
RC should be recognized as a priority marker in cardiovascular prevention, guiding future strategies to reduce residual risk in high-risk populations”
Title: A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Authors: Li Wang, Qingmei Zhang, Zhiyang Wu, Xiwei Huang
Read the full article here.
Stay informed with Hemostasis Today.
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25
-
Jan 7, 2026, 05:04Heghine Khachatryan on VWD: A Landmark in the History of Hematology
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications